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Objectives. To characterize the acute response of the vein wall to venous hypertension and associated altered fluid shear
stress and to test the effect of micronized purified flavonoid fraction (MPFF, Daflon 500), on this response.
Material and methods. A femoral arteriovenous fistula was created in Wistar rats (n¼ 48). A cohort of 24 rats received
oral treatment with MPFF (100 mg/kg/day body weight), 24 rats underwent the arteriovenous fistula procedure and re-
ceived no treatment. At days 1, 7 and 21 the animals (n¼ 8 at each time point) were killed. Experimental parameters mea-
sured included limb circumference, blood flow at the sapheno-femoral junction, leukocyte infiltration and gelatinase
activity (matrix metalloproteinase, MMP).
Results. The acute rise in venous hypertension was accompanied by limb edema and venous reflux together with an even-
tual loss of valve leaflets in the saphenous vein. There was an increase in granulocyte and macrophage infiltration into the
venous wall and the surrounding tissue, and a lesser increase in T- and B-lymphocyte infiltration. These changes were
accompanied by a local increase in the proteolytic enzymes, MMP-2 and MMP-9. Administration of MPFF reduced
the edema and lessened the venous reflux produced by the acute arteriovenous fistula. Decreased levels of granulocyte
and macrophage infiltration into the valves were also observed compared with untreated animals.
Conclusions. Venous hypertension caused by an arteriovenous fistula resulted in the development of venous reflux and an
inflammatory reaction in venous valves culminating in their destruction. MPFF was able to delay the development of re-
flux and suppress damage to the valve structures in this rat model of venous hypertension.
 2007 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.
Keywords: Venous insufficiency; Inflammation; Matrix metalloproteinase; Leucocytes; Monocytes; Lymphocytes.Introduction
Histological and immuno-cytochemical analyses of
venous valves and the venous wall from limbs
with primary venous insufficiency CEAP Class 2
suggest that lesions observed in various stages of
venous insufficiency may be associated with an in-
flammatory process.1,2 This inflammatory process is
includes early leucocyte attachment and infiltration
into the valve tissue and this ultimately leads to
fibrosclerotic remodelling of the valves and weaken-
ing of the vein wall.3 Haemodynamic forces such as
venous hypertension and modified conditions of
shear stress in the veins appear to play an important
*Corresponding author. J. J. Bergan, MD, University of California,
San Diego, 9850 Genesee Avenue, Suite 410, CA 92037-1213, La Jolla,
United States.
E-mail address: jbergan@ucsd.edu1078–5884/000102+ 09 $32.00/0  2007 Published by Elsevier Ltd orole in triggering this inflammatory reaction. The re-
action itself is characterised by early leucocyte acti-
vation.4e6 This, in turn is accompanied by synthesis
and release of many inflammatory molecules, includ-
ing proteolytic enzymes, and possibly other classes
of inflammatory regulators.7e11 The inflammatory
reaction perpetuates itself, leading to elongation
and tortuosity of the affected veins with splitting,
perforation, tearing and ultimate destruction of the
venous valves.12,13 In addition, activated inflamma-
tory mediators and endothelial cell activation may
degrade extracellular matrix constituents by release
of oxygen free radicals and matrix metalloprotei-
nases (MMPs) activity.14 Venous hypertension in-
duces morphological changes in valves, including
fibrosis, with strong MMP-2 and MMP-9 activity in
valves and during remodelling.15
In light of these mechanisms for venous remodel-
ling, therapy in the future may have to be directed
against the fundamental trigger mechanism, includingn behalf of European Society for Vascular Surgery.
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Fig. 1.Hind limb circumferential length (1 cm above the knee) as a function of time (in days) after placement of an AV fistula
in the femoral vein. Controls refer to non-pressurised saphenous veins. MMPF (Daflon) treatment was administered over
the same period of time (100 mg/kg/day, p.o.) (n¼ number of animals).leucocyte and endothelial cell activation.16 The aim is
to diminish cell activation and the magnitude of the
inflammatory response.
Daflon 500 mg, a micronized purified flavonoid
fraction (MPFF, S05682, Servier, Paris, France) consist-
ing of 90% diosmin and 10% hesperidin, is usedclinically to treat venous insufficiency and haemor-
rhoidal disorders.17,18 MPFF has been shown to reduce
the expression of adhesion molecules5,7,19 and the ad-
hesion of leucocytes to the endothelium.20,21 Recently,
it has been shown in a model of rat venous hyperten-
sion that treatment with MPFF before elevation of-40.00
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Fig. 2. Peak systolic velocity in the sapheno-femoral junction in the AV fistula group with and without MMPF (Daflon,
100 mg/kg/d) at selected times after placement of an AV fistula in the femoral vein. Positive values refer to forward
flow through the saphenous vein and its valve, negative values indicate retrograde flow, reflux through the valves and valve
leaflet failure.Eur J Vasc Endovasc Surg Vol 35, January 2008
104 L. Pascarella et al.venous pressure serves to reduce venous reflux and
the shortening of valve leaflets width.22
Thus the objectives of the current study were to
characterise the response of the vein wall to venous
hypertension with its associated altered fluid shear
stress and to test the effect of MPFF on this response.
We present measurements of limb circumference,
blood flow at the saphenofemoral junction under the
influence of hypertension generated by an arterio-
venous fistula together with measurements of leuco-
cyte infiltration of the sapheno-femoral junction and
the magnitude of gelatinase activity in the most af-
fected tissues.
Methods and Materials
Animals
The animal procedures in this study were reviewed
and approved by the Animal Subjects Committee of
the University of California San Diego. Male Wistar
rats (250e300 gm, Charles River Laboratory, Inc., Wil-
mington, MA, n¼ 48) were operated on under general
anaesthesia (pentobarbital sodium, 50 mg/kg, i.m)
without tracheotomy in order to facilitate spontane-
ous respiration.
Arterio-venous fistula
A femoral arterio-venous fistula (AVF) was placed uni-
laterally in the groin using sterile microsurgical
techniques, as described previously.15,23 Briefly, mono-
filament sutures (9e0 to 12e0, Ethicon) were used to
create a 0.5 mm fistula between the femoral artery
and vein proximal to the sapheno-femoral junction.
To minimize venous return and avoid cardiac fail-
ure after placement of the AVF, tributaries to the fem-
oral vein including the superficial epigastric vein near
the anastomosis were ligated. To prevent blood coag-
ulation, heparin was administered (1000 m/kg B.W.).
The skin incision was closed and the rats were given
intensive post-surgical care. Twenty-four rats were
housed in a light-cycle controlled flow hood cages
and maintained on standard pellet diet and water
ad libitum. A group was sacrificed at day 1, a second
group at day 7 and a third group at day 21 (n¼ 8 rat in
each group). This time period was selected following
a series of pilot studies that showed significant dys-
function in the first valve of the sapheno-femoral junc-
tion (SFJ) distal to the fistula during this 21-day time
interval and ultimately total valve destruction at 42
days. The presence of the fistula raised the blood pres-
sure at the first valve distal to the femoral vein withinEur J Vasc Endovasc Surg Vol 35, January 2008Fig. 3.Micrographs of selected histological sections (Gomori
Trichrome stain) through the femoral-saphenous venous
junction in (panel A) control animals, and after 21 day place-
ment of AVF (panel B) without and (panel C) with MPFF
treatment. Not the absence of any leaflet structure (arrows)
in the vessel lumen after exposure to chronically elevated
venous pressure (Panel B). Interstitial collages is labelled
green, cell nuclei red-purple, venous wall in green-blue.
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Fig. 4. Venous diameter at the location of the saphenous-femoral valve over the period of time of AVF placement in AVF
group, contralateral controls and in MPFF (Daflon) treated group. (n¼ number of animals).Eur J Vasc Endovasc Surg Vol 35, January 2008about 90% of the femoral arterial pressure.15,23 The
contralateral veins served as controls.
Anti-inflammatory treatment
A cohort of twenty-four rats was given an anti-inflam-
matory treatment with MPFF (Daflon 500, Servier,
Paris, France, 100 mg/kg/day body weight) using
an animal feeding tube. Treatment was started 4
days prior to placement of the AVF and continued un-
til completion of the study. Two groups of animals
were formed. Group 1 consisted of animals with
a femoral AVF without anti-inflammatory treatment,
and Group 2 consisted of animals with femoral AVF
and treatment with MPFF. The venous tissue was col-
lected under general anaesthesia (pentobarbital so-
dium, 50 mg/kg, i.m.) for analysis at day 1, 7 and 21
after placement of the AVF (n¼ 8 rats in each group).
The contralateral veins served as controls.
Venous reflux examination
At the end of each time period, Duplex Ultrasound
examination was carried out in each animal under
general anaesthesia (pentobarbital sodium, 50 mg/
kg i.p.). The ultrasound system (Philips HDI 5000,
Philips Medical Systems, Bothell, WA) was used
with a 7e15 MHz hockey-stick transducer. Transverse
and longitudinal scans of the femoral venous system
of both lower limbs were made. The examination
included imaging of the fistula, femoral artery and
sapheno-femoral junction. Blood velocities were mea-
sured in sapheno-femoral junction 0.5 cm distal to theterminal valve. The diameters of the terminal valve
annulus were recorded.
Immunohistochemistry
Specimens from the sapheno-femoral junction were
freshly frozen in liquid nitrogen and stored at
70 C until examination. Longitudinal sections
(7 mm thickness) were cut across the valve leaflets
with a cryostat at 23 C, air dried for 30minutes,
and fixed in purified acetone for 10 minutes.
Terminal valve morphology was analyzed by the
Gomori Trichrome stain on the fixed sections. Leuco-
cyte infiltrationwas determined by labeling the section
with monoclonal antibodies against granulocytes
(mouse anti-Rat Gran/Erythroid cells, MCA967,
Serotec, Raleigh, North Carolina), macrophages/
monocytes (mouse anti-rat CD68, MCA341 R, Serotec),
T-lymphocytes (mouse anti-rat CD3, MR5300, Caltag
Laboratories, Burlingame, CA), B-lymphocytes (mouse
anti-rat CD45RA, MR6400, Caltag Laboratories). Sec-
ondary antibodies with fluorescent label (Alexa Fluor
488, Goat Anti-Mouse, A21042, Invitrogen Carlsbad,
CA; Alexa Fluor 594 goat anti-mouse, A21125, Invitro-
gen) were used. Prior to cover-slipping, Prolong Gold
with DAPI (P363931; 40,6-diamidino-2-phenylindole
dihydrochloride; Invitrogen) was applied to enhance
fluorescence preservation.
The sections were examined with an inverted fluo-
rescent microscope (Olympus IX70, Olympus Center
Valley, PA) with 3 filter sets (green 495/519 nm; red
w590/617 nm; blue DAPI 330e380 nm) at objective
magnifications between 10X and 60X. Images were
106 L. Pascarella et al.captured with a color couple charge camera, digitized
on a laboratory computer (Powerbook G4; Apple
Computer Inc. Cupertino, Ca) and analyzed using
NIH Image Software (National Institute of Health, Be-
thesda, Maryland).
In situ zymography
Gelatinase activity was detected in situ by visualisa-
tion of fluorescence from the proteolytic cleavage of
intramolecularly quenched fluorescein isothiocyanate
(FITC)-labeled DQ-gelatin (Molecular Probes). Briefly,
7 mm frozen tissue sections were equilibrated at room
-temperature and overlaid with a 20 ml solution con-
taining 20 ml/l FITC DQ-Gelatin in 20 mmol/L
NaCl, 5 mmol/L CaCl2, 0.2 mmol/L NaN3, 0.02%
Brj35, and 0.5% low melting point agarose. The sec-
tions were then cover-slipped, allowed to gel for
5minutes at 4 C and incubated for 24 hours at
37 C. The sections were incubated in presence of ac-
tivation buffer (100 mM NaCl, 100 mM Tris-HCl, pH
7.5, 10 mM CaCl2, 20 mM ZnCl2, and 0.05% w/v
Brij 35 detergent). A part of the sections were incu-
bated in the presence of the metallo-proteinase inhib-
itor ethylenediaminotetracetate (EDTA, 10 mmol/L).
The sections were examined with an inverted (green
filter, 495/519 nm) fluorescent microscope at several
objective magnifications up to 60X. Images were re-
corded digitally and analyzed (NIH Image Software,
National Institute of Health) on a laptop computer
(Powerbook G4; Apple Computer Inc. Cupertino,
Ca). Gelatinase activity was determined by fluores-
cent intensity measurements in three different re-
gions: the femoral vein, sapheno-femoral junction,
and the great saphenous vein.
Statistics
Measurements are presented as mean and standard
deviation. For each parameter, descriptive statistics
are provided at each time by treatment group. Differ-
ences between treatments were studied at each time
using a two-sided Student’s t test for independent
samples. p< 0.05 was considered to be statistically
significant.
Results
Tissue oedema and blood velocity
Limb oedema, as measured by circumferential length
1 cm above the knee joint, progressively increased
over the 21-day observation period in the groupEur J Vasc Endovasc Surg Vol 35, January 2008AVF when compared to control contralateral group
with a significant difference at day 14 and day 21
( p< 0.001). In the group treated with MPFF, the cir-
cumference did not increase between day 1 and day
21 compared to the AVF group ( p< 0.001) (Fig. 1).
Using ultrasound measurements, the average
blood velocity (cm/sec) in the sapheno-femoral junc-
tion was markedly increased at 14 and 21 days in
the AVF group when compared to contralateral con-
trols without AVF ( p< 0.001). The group treated
with MPFF showed increased sapheno-femoral reflux
compared with controls at day 21 ( p¼ 0.009), but this
reflux was less than in the AVF group at day 21
( p< 0.001) (Fig. 2).
The development of the reflux at 21 days indicates
loss of valve function at the sapheno-femoral junction,
which was confirmed by selected histological sections
Fig. 5. Micrograph of immunohistological section through
sapheno-femoral junction after 21 days of exposure to ele-
vated blood pressure due to the AV fistula (a) without and
(b) with MMPF treatment. The sections show fluorescently
labelled antibody against granulocytes (G) superimposed
on DAPI labelled cell nuclei (insert B in blue colour). Gran-
ulocytes were identified by requirement for superposition of
the green and blue fluorescence (insert A). Note attenuation
of the infiltration by the MPFF.
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Fig. 6. Time course of leucocyte (macrophages, granulocytes, B-,T-lymphocytes) infiltration in the sapheno-femoral junction
after placement of an AV fistula. The cell number is expressed per tissue area (mm2). (n¼ number of animals).showing the absence of any valve leaflets (Fig. 3).
Valve leaflets were observed after 21 day in the pres-
ence of MPFF treatment.
Valve diameter
The valve diameter increased between day 7 to day 21
in the AVF group when compared to controls
( p< 0.001). The MPFF treatment group had a slower
increase in diameter with less augmentation com-
pared to the AVF group animals at day 14 and day
21 ( p< 0.001) (Fig. 4).
Leucocyte infiltration
In the tissue of the AVF group surrounding the sa-
pheno-femoral junction and a small part of the femo-
ral vein, there was over the period of 21 days
a progressive increase in granulocyte infiltration
( p¼ 0.023 between day 1 and day 21) (Figs. 5a, 6).
In this group, a plateau of infiltration was reached at
day 7 which then persisted but did not increase fur-
ther. In the AVF group an increase in the number of
macrophages/monocytes was seen between day 1
and 7, followed by a plateau until day 21 (Fig. 6).
We saw an increase of T lymphocytes (by about
37%) ( p< 0.001 between day 1 and day 21 but only
a small non-significant increase in B-lymphocyte infil-
tration in the sapheno-femoral junction at day 1 and 7
in the AVF group.
Comparedwith the untreatedAVF group, treatment
with MPFF decreased granulocyte and macrophageinfiltration into the sapheno-femoral parenchyma at
each time point (p values between 0.028 and 0.004 for
granulocytes; p values between 0.022 and 0.001 at
day 1 and day 21 for marcrophages) (Figs. 5b, 7). Treat-
ment with MPFF decreased B-lymphocyte infiltration
only at day 1 compared to the untreated AVF group
(results not shown).
In situ zymography
In the AVF group, the gelatinolytic activity (MMP2
and MMP9) in the femoral vein (Region 1), the sa-
pheno-femoral junction (Region 2), and greater saphe-
nous vein (Region 3) was enhanced on days 1
( p¼ 0.016 region 1, p¼ 0.001 region 2), 7 ( p< 0.001 re-
gion 1, p¼ 0.073 region 2, p¼ 0.001 region 3) and 21
( p< 0.001 region 1, p< 0.001 region 2, p¼ 0.005 region
3) as compared to contralateral controls (Fig. 8). The
activity was blocked below detection limit in the pres-
ence of the metal chelator EDTA (Fig. 8). Treatment
with MPFF did not inhibit gelatinolytic activity in
the different sites (results not shown).
Discussion
While the A-V fistula model is not a perfect represen-
tation of human venous hypertension, it is the only
chronic venous hypertension that allows serial obser-
vations over time. Placement of a femoral AVF causes
stretch of the venous wall due to a significant pressure
elevation and likely also changes the fluid shear stress
on the endothelium in the venous vasculature of theEur J Vasc Endovasc Surg Vol 35, January 2008
108 L. Pascarella et al.Fig. 7. Time course of granulocyte (top graph) and macrophage/monocyte (bottom) density (number of cells per tissue area,
mm2) into the sapheno-femoral junction without and with MPFF (Daflon) treatment after placement of an AV fistula.
(n¼ number of animals).limb. This in turn is accompanied by limb edema and
an increase in limb circumference together with an
eventual loss of valve leaflets in the saphenous vein.
There is an increase in granulocyte and macrophage
infiltration into the wall and the surrounding tissue
and a lesser but still detectable increase in T- and B-
lymphocyte infiltration. These changes are all attenu-
ated by oral administration of MPFF. The observations
corroborate previous observations regarding venous
valve remodelling under the influence of venous hy-
pertension16 and in addition confirm the ameliorating
effect of MPFF on venous insufficiency. The oedema
as measured by limb circumference was significantly
reduced with preservation of valve function.
The observations in this study suggest that acute
venous hypertension in the femoral vein induced by
an AV fistula is accompanied by inflammatoryEur J Vasc Endovasc Surg Vol 35, January 2008markers. Markers of inflammation in form of T-cell,
granulocyte, and macrophage infiltration into the
vein wall are seen. The situation resembles valve fail-
ure and venous insufficiency in man except that in this
acute model granulocyte infiltration is encountered. In
chronic venous insufficiency in man the predominant
cell infiltrating the venous valve is the monocyte.2 This
lack of neutrophil detection may in part be due to the
fact that there is currently no technique in patients to
detect neutrophil or any other leucocyte infiltration
in-vivo over a prolonged period of time. Instead the
analysis has to rely on biopsies obtained at single
time points during the progression of the disease. Leu-
cocyte infiltration into the femoral vein and the SFJ as
seen in this model is one of the hallmarks of the in-
flammatory process and in line with previous histo-
logical observations in the valves and venous wall of
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group. n¼ 4 rats in each group.Eur J Vasc Endovasc Surg Vol 35, January 2008patients with venous dysfunction.2 The response of
the leucocytes in man is probably preceded by a set
of separate inflammatory events in the acute phase
of venous pressure elevation, as seen in the present
model but the acute phase and its preliminary events
are currently not capable of being studied.
The current model represents a severe form of
venous pressure elevation. Likely, the stress-induced
inflammation is greater in this model than what is
encountered in man. An exception may be at the an-
kle in man and in perforating veins where the pres-
sures encountered are comparable to those in this
experimental preparation.24 Pressures in perforating
veins caused by muscular contraction are comparable
to those generated in this model.24In previous studies,22 we reported expansion of the
venous wall under elevated pressure generated by
the AVF. In the early stages after placement of the
AVF the valve leaflets were still able to close properly
without significant reflux. Thus the elevated pressure
per se is not the only variable that compromises the leaf-
lets although it may produce a progressive expansion
of the venous diameter to the point that the length of
the leaflets may be insufficient to achieve complete clo-
sure. At the time the leaflets fail and reflux occurs, we
see a reduction of the leaflet dimensions in a sequence
of events that leads to valve destruction, much as is
seen in man.25 Destruction of the valve leaflets may
be induced not only by stretch of the venous wall and
the leaflets but also by the onset of an abnormal fluid
110 L. Pascarella et al.shear stress on the endothelial surface of the leaflets. As
the valve ceases to close completely a reversed shear
stress may arise during venous reflux. Fluid shear
stress on the endothelium, if accompanied by unsteady
retrograde (with instances of reversed shear direc-
tion)26 or even turbulent (with random fluctuation)
stress,27may be an inflammatory stimulus for the endo-
thelial cells on a valve leaflet and may trigger cell apo-
ptosis, degradation of the collagen matrix of the valve,
and consequentlymechanical softening and restructur-
ing of the leaflets and the venous wall.
MPFF administration reduced the oedema, the valve
annulus diameter, and fistula blood flow produced by
the acute AVF in line with its ability to block elevation
of microvascular permeability in inflammation.28,29
MPFF also reduces granulocyte and macrophage infil-
tration in line with observations in experimental acute
ischemia and reperfusion or ischemia produced by
venous hypertension.21 The current AVF model
brought to light the ability ofMPFF to attenuate infiltra-
tion into the vein wall and valves as well. These activ-
ities by a combination of flavonoids are in line with
the hypothesis that an early inflammatory signal is
being blocked. The exact nature of this signal remains
to be identified. Meanwhile our observation suggest
that blocking the remodelling of venous valves and
the vein wall in venous insufficiency in manmay serve
to shift the therapeutic approach from treatment to an
earlier stage of intervention.
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